ABBOTT LABORATORIES Net Cash Provided by (Used in) Investing Activities, Continuing Operations
ABBOTT LABORATORIES (ABT) reported Net Cash Provided by (Used in) Investing Activities, Continuing Operations of -$6.08 billion for the 12-month period ending 2012-12-31, per its 10-K filed 2013-02-15.
Discontinued › Cash Flow › Investing Activities
us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations · last filed 2013-02-15
- ABBOTT LABORATORIES net cash provided by (used in) investing activities, continuing operations for the quarter ending 2012-12-31 was -$1.23B, a 189.81% decline year-over-year.
- ABBOTT LABORATORIES net cash provided by (used in) investing activities, continuing operations for the quarter ending 2012-09-30 was -$531.61M, a 153.59% decline year-over-year.
- ABBOTT LABORATORIES net cash provided by (used in) investing activities, continuing operations for the quarter ending 2012-06-30 was $688.37M, a 234.82% increase year-over-year.
- ABBOTT LABORATORIES net cash provided by (used in) investing activities, continuing operations for the quarter ending 2012-03-31 was -$5.01B.
- ABBOTT LABORATORIES net cash provided by (used in) investing activities, continuing operations for fiscal 2012 was -$6.08B, a 2431.50% decline from fiscal 2011.
- ABBOTT LABORATORIES net cash provided by (used in) investing activities, continuing operations for fiscal 2011 was $260.83M.
- ABBOTT LABORATORIES net cash provided by (used in) investing activities, continuing operations for fiscal 2010 was -$12.19B.
- ABBOTT LABORATORIES net cash provided by (used in) investing activities, continuing operations for fiscal 2009 was -$3.70B.
| Period end | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 3 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 6 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 9 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 12 month |
|---|---|---|---|---|
| 2012-12-31 | -$1.23B derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-15 | -$1.76B derived: sum of 2 quarters · filed 2013-02-15 | -$1.07B derived: sum of 3 quarters · filed 2013-02-15 | -$6.08B 10-K · filed 2013-02-15 |
| 2012-09-30 | -$531.61M derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-07 | $156.76M derived: sum of 2 quarters · filed 2012-11-07 | -$4.86B 10-Q · filed 2012-11-07 | -$3.49B derived: sum of 4 quarters · filed 2013-02-15 |
| 2012-06-30 | $688.37M derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-07 | -$4.32B 10-Q · filed 2012-08-07 | -$2.96B derived: sum of 3 quarters · filed 2013-02-15 | -$1.97B derived: sum of 4 quarters · filed 2013-02-15 |
| 2012-03-31 | -$5.01B 10-Q · filed 2012-05-08 | -$3.65B derived: sum of 2 quarters · filed 2013-02-15 | -$2.66B derived: sum of 3 quarters · filed 2013-02-15 | -$2.45B derived: sum of 4 quarters · filed 2013-02-15 |
| 2011-12-31 | $1.36B derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-15 | $2.36B derived: sum of 2 quarters · filed 2013-02-15 | $2.56B derived: sum of 3 quarters · filed 2013-02-15 | $260.83M 10-K · filed 2013-02-15 |
| 2011-09-30 | $992.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-07 | $1.20B derived: sum of 2 quarters · filed 2012-11-07 | -$1.10B 10-Q · filed 2012-11-07 | -$3.54B derived: sum of 4 quarters · filed 2013-02-15 |
| 2011-06-30 | $205.59M derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-07 | -$2.10B 10-Q · filed 2012-08-07 | -$4.54B derived: sum of 3 quarters · filed 2013-02-15 | |
| 2011-03-31 | -$2.30B 10-Q · filed 2012-05-08 | -$4.74B derived: sum of 2 quarters · filed 2013-02-15 | ||
| 2010-12-31 | -$2.44B derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-15 | -$12.19B 10-K · filed 2013-02-15 | ||
| 2010-09-30 | -$9.75B 10-Q · filed 2011-11-04 | |||
| 2009-12-31 | -$3.70B 10-K · filed 2012-02-21 | |||
| 2008-12-31 | -$2.09B 10-K · filed 2010-02-19 | |||
| 2007-12-31 | -$1.14B 10-K · filed 2010-02-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |